powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Karolinska Institutet, Institut De Recherches Internationales Servier IRIS

Conditions

"Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Acute ischemic strokeMyelodysplastic Syndrome (MDS)/AMLor Chronic Myelomonocytic Leukemia (CMML)"

Phase 1

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)

CompletedCTIS2024-514356-33-00

Institut De Recherches Internationales Servier IRISMyelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)", "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Start: 2025-02-11End: 2025-10-13Target: 54Updated: 2025-08-04

Phase 3

A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke

SuspendedCTIS2023-506178-11-00

Karolinska InstitutetAcute ischemic stroke

Start: 2025-11-11Target: 680Updated: 2023-11-07